Liu Xiang-Dong, Zhou Xiao-Dong, Wang Zhi, Shen Yong-Ming
Department of Ophthalmology, Affiliated Jinshan Hospital, Fudan University, Shanghai 201508, China.
Int J Ophthalmol. 2016 Jan 18;9(1):132-8. doi: 10.18240/ijo.2016.01.22. eCollection 2016.
To assess possible benefits of intravitreal triamcinolone acetonide (IVTA) injection as pretreatment for macular laser photocoagulation (MLP) in patients with diabetic macular edema (DME).
Published randomized controlled trials (RCTs) concerning MLP with or without IVTA pretreatment for DME were retrieved from databases CNKI, Medline, EMbase, Web of Science, and the Cochrane Library. A Meta-analysis on eligible studies was conducted using RevMan 5.0 software. Two investigators independently assessed the quality of the trials and extracted data. Main outcome measures included the change in best corrected visual acuity (BCVA), difference in central macular thickness (CMT) and adverse events reporting in particular elevated intraocular pressure within the follow-up period. The results were pooled using weight mean difference (WMD) or odds risk (OR) with their corresponding 95% confidence intervals (CI). A fixed- or random-effect model was employed depending on the heterogeneity of the inclusion trials.
Finally, five independent RCTs were identified and used for comparing MLP with IVTA pretreatment (131 eyes) with MLP alone (133 eyes, control group). The overall study quality was relatively higher according to the modified Jadad scale. The Meta-analysis showed that MLP with IVTA pretreatment significantly reduced CMT at one, three and six months (P=0.002, 0.0003 and 0.04, respectively), compared with MLP alone. The IVTA pretreatment group showed statistically significant improvements in BCVA at the one-month follow up as compared with the control group (P=0.03). At three- and six-month follow up, there was a beneficial trend towards improving visual acuity in the IVTA pretreatment group without statistical significance between groups (P=0.06 and 0.20, respectively). The incidence of elevation of intraocular pressure was significantly higher in the IVTA pretreatment group than in the control group (P<0.0001). No evidence of publication bias was present according to Begg's test and Egger's test. There was a low level of heterogeneity in the included studies.
This Meta-analysis indicates that MLP with IVTA pretreatment has a better therapeutic effect in terms of CMT reduction and earlier (1mo) visual improvement for patients with DME as compared with MLP alone. Further confirmation with rigorously well-designed multi-center trials is needed.
评估玻璃体内注射曲安奈德(IVTA)作为糖尿病性黄斑水肿(DME)患者黄斑激光光凝(MLP)预处理的潜在益处。
从中国知网、Medline、EMbase、科学引文索引和考克兰图书馆数据库中检索已发表的关于DME接受或未接受IVTA预处理的MLP随机对照试验(RCT)。使用RevMan 5.0软件对符合条件的研究进行Meta分析。两名研究人员独立评估试验质量并提取数据。主要观察指标包括最佳矫正视力(BCVA)的变化、中心黄斑厚度(CMT)的差异以及随访期内不良事件的报告,特别是眼压升高情况。结果采用加权均数差(WMD)或比值比(OR)及其相应的95%置信区间(CI)进行合并。根据纳入试验的异质性采用固定效应模型或随机效应模型。
最终确定了5项独立的RCT,用于比较IVTA预处理的MLP(131只眼)与单纯MLP(133只眼,对照组)。根据改良Jadad量表,总体研究质量相对较高。Meta分析显示,与单纯MLP相比,IVTA预处理的MLP在1个月、3个月和6个月时显著降低了CMT(分别为P = 0.002、0.0003和0.04)。与对照组相比,IVTA预处理组在1个月随访时BCVA有统计学显著改善(P = 0.03)。在3个月和6个月随访时,IVTA预处理组有视力改善的有益趋势,但组间无统计学意义(分别为P = 0.06和0.20)。IVTA预处理组眼压升高的发生率显著高于对照组(P < 0.0001)。根据Begg检验和Egger检验,没有发表偏倚的证据。纳入研究的异质性水平较低。
本Meta分析表明,与单纯MLP相比,IVTA预处理的MLP在降低CMT和使DME患者更早(1个月)改善视力方面具有更好的治疗效果。需要通过严格设计的多中心试验进行进一步验证。